Navigation Links
Potential Cure for HIV Discovered

then cease to produce the virus for months or even years.

"Numerous attempts have been made to activate these cells, with the hope that such strategies would sensitize the accompanying viruses to antiviral drugs, leading to virus eradication," Engelman wrote. "Advances with such approaches in patients have been slow to materialize."

New experiments must be designed to see if the Tre enzyme can be used to recognize these dormant infected cells, he wrote.

"Although favorable results would represent perhaps only a baby step toward eventual use in patients, the discovery of the Tre recombinase proves that enzymatic removal of integrated HIV-1 from human chromosomes is a current-day reality," he said.

The researchers who developed the enzyme were optimistic about their ability to design additional enzymes which would target other parts of the virus's DNA.

However they warned that there were significant barriers to overcome before the enzyme could be used to help cure patients.

"The most important, and likely most difficult, among these is that the enzyme would need efficient and safe means of delivery and would have to be able to function without adverse side effects," wrote lead author Indrani Sarkar of the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden.

"Nevertheless the results we present offer an early proof of principal for this type of approach, which we speculate might form a useful basis for the development of future HIV therapies," Sarkar concluded.


'"/>




Page: 1 2

Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. Potential Benefits Of New Nanotechnology
11. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Potential Cure for HIV Discovered

Other Medicine News:Health News:NutraCea Announces Third Quarter 2008 Financial Results 2Health News:NutraCea Announces Third Quarter 2008 Financial Results 3Health News:NutraCea Announces Third Quarter 2008 Financial Results 4Health News:NutraCea Announces Third Quarter 2008 Financial Results 5Health News:NutraCea Announces Third Quarter 2008 Financial Results 6Health News:NutraCea Announces Third Quarter 2008 Financial Results 7Health News:NutraCea Announces Third Quarter 2008 Financial Results 8Health News:NutraCea Announces Third Quarter 2008 Financial Results 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:Misys Wins 'Best Trade Processing Product' Accolade in European Banking Technology Readers' Choice Awards 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 3Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 4Health News:More People Living Longer After Cancer Diagnosis 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 3
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Warner Chilcott Announces Secondary Equity Offering 6242 1Warner Chilcott Announces Secondary Equity Offering 6242 2Warner Chilcott Announces Secondary Equity Offering 6242 3Warner Chilcott Announces Secondary Equity Offering 6242 4Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 1Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 2Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 3Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 1Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 2Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 3Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 5Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 6Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 7
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 2Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 3